Lipids and apolipoproteins C-III and E among treatment-naïve and treatment-experienced persons with HIV in Nigeria
暂无分享,去创建一个
[1] J. Shalhoub,et al. Trends of HIV Mortality between 2001 and 2018: An Observational Analysis , 2021, Tropical medicine and infectious disease.
[2] Zemenu Tamir,et al. Prevalence of dyslipidaemia among HIV-infected patients receiving combination antiretroviral therapy in North Shewa, Ethiopia , 2021, PloS one.
[3] C. Lindan,et al. Prevalence and factors associated with hypertension among people living with HIV/AIDS on antiretroviral therapy in Uganda , 2021, The Pan African medical journal.
[4] Temesgen Fiseha,et al. Hypertension in HIV-Infected Patients Receiving Antiretroviral Therapy in Northeast Ethiopia , 2019, International journal of hypertension.
[5] M. Fukunaga,et al. Apolipoprotein E-related glomerular disorders. , 2019, Kidney international.
[6] N. Lundbom,et al. Role of apolipoprotein C‐III overproduction in diabetic dyslipidaemia , 2019, Diabetes, obesity & metabolism.
[7] D. Heimburger,et al. Patho-immune Mechanisms of Hypertension in HIV: a Systematic and Thematic Review , 2019, Current Hypertension Reports.
[8] A. Dalgleish,et al. Serum Apolipoprotein E and Other Inflammatory Markers Can Identify Non-Responding Patients to a Dendritic Cell Vaccine12 , 2018, Translational oncology.
[9] P. Reiss,et al. Hypertension in people living with HIV , 2017, Current opinion in HIV and AIDS.
[10] Daoquan Peng,et al. The emerging role of apolipoprotein C-III: beyond effects on triglyceride metabolism , 2016, Lipids in Health and Disease.
[11] A. Kamuhabwa,et al. Lipid Profile in HIV-Infected Patients Using First-Line Antiretroviral Drugs , 2016, Journal of the International Association of Providers of AIDS Care.
[12] P. Greenland,et al. Isolated systolic hypertension in young and middle-aged adults and 31-year risk for cardiovascular mortality: the Chicago Heart Association Detection Project in Industry study. , 2015, Journal of the American College of Cardiology.
[13] D. Coelho,et al. Analysis of the prevalence of dyslipidemia in individuals with HIV and its association with antiretroviral therapy. , 2014, Revista da Sociedade Brasileira de Medicina Tropical.
[14] M. Verma,et al. Alteration in Lipid Profile in Treatment-Naive HIV-Infected Patients and Changes Following HAART Initiation in Haryana , 2014 .
[15] O. Oguejiofor,et al. Dyslipidemia in Nigeria: prevalence and pattern. , 2012, Annals of African medicine.
[16] H. Taniguchi,et al. Relationship between age and metabolic disorders in the population of Bali , 2011 .
[17] W. Fawzi,et al. Dyslipidemia in an HIV-Positive Antiretroviral Treatment-Naive Population in Dar es Salaam, Tanzania , 2011, Journal of acquired immune deficiency syndromes.
[18] Arun Kumar,et al. Assessment of lipid profile in patients with human immunodeficiency virus (HIV/AIDS) without antiretroviral therapy , 2011 .
[19] B. Ances,et al. Hypertriglyceridemia in combination antiretroviral-treated HIV-positive individuals: potential impact on HIV sensory polyneuropathy , 2011, AIDS.
[20] A. Minihane,et al. Apolipoprotein E genotype and hepatitis C, HIV and herpes simplex disease risk: a literature review , 2010, Lipids in Health and Disease.
[21] J. Kastelein,et al. Triglycerides and Cardiovascular Risk , 2009, Current cardiology reviews.
[22] S. Liu,et al. Prevalence of and Risk Factors for Isolated Systolic Hypertension in the Rural Adult Population of Liaoning Province, China , 2008, The Journal of international medical research.
[23] A. D. de Craen,et al. ApoE Plasma Levels and Risk of Cardiovascular Mortality in Old Age , 2006, PLoS medicine.
[24] N. Klein,et al. Early Structural and Functional Changes of the Vasculature in HIV-Infected Children: Impact of Disease and Antiretroviral Therapy , 2005, Circulation.
[25] E. Hawe,et al. Nonfasting Apolipoprotein B and Triglyceride Levels as a Useful Predictor of Coronary Heart Disease Risk in Middle-Aged UK Men , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[26] P. Fu,et al. Enzymatic determination of total serum cholesterol. , 1974, Clinical chemistry.
[27] G Bucolo,et al. Quantitative determination of serum triglycerides by the use of enzymes. , 1973, Clinical chemistry.
[28] R. Levy,et al. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.
[29] G. Amusa,et al. Cardiovascular Risk Factors in HIV-Infected Adults in North-Central Nigeria: Prevalence, Associated Factors and Assessment of Risk Using the Framingham Risk Score – Preliminary Results from a Survey , 2021 .
[30] B. Myke-Mbata,et al. Gender Comparison Of Apolipoprotein And Lipid Profiles In Hiv Seropositives In Nauth Nnewi, South Eastern Nigeria , 2021 .
[31] A. Nayyar,et al. Dyslipidemia in HIV infected and AIDS patients: Association of serum lipids with HIV status, a cross-sectional study , 2019, Journal of Medicine in the Tropics.
[32] I. Ezeugwunne,et al. Evaluation of Apolipoprotein and Lipid Profiles in HIV Symptomatic Subjects Before and After 12 Months Antiretroviral Therapy in NAUTH Nnewi, South Eastern Nigeria , 2019 .
[33] R. Yusuf,et al. Lipid profile of HIV/AIDS patients attending antiretroviral clinic in Zaria, North-Western Nigeria , 2014 .
[34] C. Daniyam,et al. Lipid Profile of Anti-Retroviral Treatment-Naïve HIV-Infected Patients in Jos, Nigeria , 2013, Annals of medical and health sciences research.
[35] J. Ferrières,et al. The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Apoprotein C-III and E-Containing Lipoparticles Are Markedly Increased in HIV-Infected Patients Treated with Protease Inhibitors: Association wi , 1999 .